Fast Five Quiz: Castration-Resistant Prostate Cancer

Kyle A. Richards, MD


December 02, 2020

PSA doubling time is a strong predictor of metastases in patients with nmCRPC, which is defined as CRPC with no visible metastatic disease according to conventional imaging. For this group of patients, a PSA doubling time of 10 months or less is associated with a high risk of developing metastatic disease or dying from prostate cancer.

For men with advanced prostate cancer, a blood chemistry profile including serum creatinine level and liver function tests may be useful.

Learn more about mCRPC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.